Copyright © 2013 Knight Sac Media. All rights reserved.http://www.siliconinvestor.com/subject.aspx?subjectid=24574 Wallets are bulging and pipelines are thin at some big pharma and big biotechs. Third tier biotechs are cheap - some with good science are trading at near book. Does this combination mean that Daddy Pharma and Momma Biotech might go a huntin'? This thread is for the discussion of possible hunter...http://www.siliconinvestor.com/images/Logo380x132.pnghttp://www.siliconinvestor.com/subject.aspx?subjectid=2457438013210Ian@SIWCRX up about 25% Actavis Inc. ( ACT ), a big maker of generic drugs that was an acquisition target a month ago, is in early talks about a potential acquisition of Irish drug maker Warner Chilcott PLC ( WCRX ), a person familiar with the matter said. The talks come weeks after Valeant Pharmaceuticals Inter...http://www.siliconinvestor.com/readmsg.aspx?msgid=288873705/10/2013 3:38:47 PMmopgcwBayer to Buy Conceptus for $1.1 BillionBayer of Germany plans to buy the American birth control company Conceptus for about $1.1 billion. Bayer said it would offer Conceptus shareholders $31 for each of their shares in the company, or 20 percent more than the closing share price on Fridayhttp://www.siliconinvestor.com/readmsg.aspx?msgid=288650044/29/2013 4:13:50 PMDewDiligence_on_SITable of Recent Biotech Buyouts and Premiums (updated for revised VRX-OMPI): investorshub.advfn.com  http://www.siliconinvestor.com/readmsg.aspx?msgid=288296194/11/2013 5:02:44 PMnigel batesObagi Medical Products, Inc. ( OMPI) (the “Company” or “Obagi”) today announced that Obagi and Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. Pursuant to the amendment, Valeant increased its offer to acquire al...http://www.siliconinvestor.com/readmsg.aspx?msgid=288131894/3/2013 9:44:05 AMnigel batesAZN buys private company Alphacore for an undisclosed sum. uk.finance.yahoo.com  Interesting lead product: October 9, 2012 (Ann Arbor, MI) — AlphaCore Pharma, announced today that results from the company’s Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the dr...http://www.siliconinvestor.com/readmsg.aspx?msgid=288129284/3/2013 3:38:56 AMsim1 Royalty Pharma Announces Proposal To Acquire ElanAnnouncement Made Under Rule 2.4 of Irish Takeover Rules [graphic]Press Release: Royalty Pharma – 1 hour 26 minutes ago Email Print RELATED QUOTES SymbolPriceChangeELN10.60 [graphic] NEW YORK, Feb. 25, 2013 /PRNewswire/ -- RP Management, LLC ("...http://www.siliconinvestor.com/readmsg.aspx?msgid=287447282/25/2013 6:03:27 AMnigel batesCARY, NC--(Marketwire - Feb 20, 2013) - Cornerstone Therapeutics Inc. ( NASDAQ : CRTX ) (the "Company") announced today that its Board of Directors has received a letter from Chiesi Farmaceutici SpA ("Chiesi"). In that letter Chiesi, which owns approximately 60% of the outstanding shares of the Company's common stock, ...http://www.siliconinvestor.com/readmsg.aspx?msgid=287356082/20/2013 9:00:52 AMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=286808641/22/2013 9:27:21 PMDewDiligence_on_SITable of recent biotech buyouts and premiums (updated for AGN-MAPP): investorshub.advfn.com http://www.siliconinvestor.com/readmsg.aspx?msgid=286808631/22/2013 9:26:38 PMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=286808621/22/2013 9:25:37 PMnigel batesSAN RAFAEL, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it has acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan and glycolipid metabolism. Zacharon drug discover...http://www.siliconinvestor.com/readmsg.aspx?msgid=286479161/7/2013 9:28:21 AMnigel batesllumina, Inc. (ILMN) today announced that it has signed a definitive agreement to acquire Verinata Health, Inc., a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities, for consideration of $350 million plus up to $100 million in milestone payments through 2015. Upon co...http://www.siliconinvestor.com/readmsg.aspx?msgid=286479061/7/2013 9:25:23 AMnigel batesGilead Sciences (GILD) and YM BioSciences (YMI) announced that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM’s Board of Directors, and values YM at approximately $510M, with YM reporting C$12...http://www.siliconinvestor.com/readmsg.aspx?msgid=2859873012/12/2012 8:56:52 AMscaram(o)uchehttp://www.siliconinvestor.com/readmsg.aspx?msgid=2859487712/10/2012 10:56:23 AMnigel batesTHOUSAND OAKS, Calif. (AP) -- Biotech drug maker Amgen is buying human genetics research and analytics company deCODE Genetics for $415 million. DeCODE, based in Reykjavik, Iceland, has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer "DeCODE Genetics has built a wo...http://www.siliconinvestor.com/readmsg.aspx?msgid=2859477912/10/2012 10:20:51 AMnigel batesGhent, Belgium – 21 September 2012, 7am CET – Devgen nv (Euronext Brussels: DEVG), the agro- biotech company that shapes the field of hybrid rice in India and Southeast Asia and innovates in crop protection technologies, today reports that Syngenta has announced an offer to acquire all outstanding shares of De...http://www.siliconinvestor.com/readmsg.aspx?msgid=284238849/21/2012 4:03:04 AMmopgcwwsj: Valeant Pharmaceuticals International Inc. VRX.T +14.80% has agreed to buy Medicis Pharmaceutical Corp. MRX +38.31% for $2.6 billion, the latest in a string of acquisitions that have transformed the Canadian drug maker into a multibillion-dollar global company. Valeant, based in Montreal, will pay $44 a share fo...http://www.siliconinvestor.com/readmsg.aspx?msgid=283837189/4/2012 5:19:31 PMmopgcwhttp://www.siliconinvestor.com/readmsg.aspx?msgid=282697237/16/2012 10:38:23 AMDewDiligence_on_SITable of recent biotech buyouts and premiums (updated for HGSI and PRX deals): investorshub.advfn.com http://www.siliconinvestor.com/readmsg.aspx?msgid=282696307/16/2012 10:05:22 AMDewDiligence_on_SITable of recent biotech buyouts and premiums (updated for BMY-AMLN deal): investorshub.advfn.com http://www.siliconinvestor.com/readmsg.aspx?msgid=282604207/11/2012 6:03:44 PMBiotech JimNot that I am aware, only speculation on my part. That is, rampant speculation. Other speculations on who might be in play (besides those mentioned today in the reports): VVUS (if QNEXA approval), ONXX (despite the comparator trial with Velcade), MDVN.http://www.siliconinvestor.com/readmsg.aspx?msgid=282423347/2/2012 4:02:50 PMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=282423167/2/2012 3:56:41 PMBiotech JimIt seems that the market thinks today that INCY may be next. After all, Paul F. wants to retire soon.http://www.siliconinvestor.com/readmsg.aspx?msgid=282421877/2/2012 3:05:34 PMDewDiligence_on_SIBMRN, AFFY, THRX, and RIGL are the most likely candidates for the next significant biotech buyout, according to Piper Jaffray: investorshub.advfn.com http://www.siliconinvestor.com/readmsg.aspx?msgid=282421817/2/2012 3:03:28 PMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=282421797/2/2012 3:03:10 PMmopgcwhttp://www.siliconinvestor.com/readmsg.aspx?msgid=281696885/25/2012 5:17:44 PMnigel batesMELBOURNE, AUSTRALIA--(Marketwire -04/23/12)- Biota Holdings Limited (ASX: BTA.AX - News) and Nabi Biopharmaceuticals (NASDAQ: NABI - News) today announced the signing of a Merger Implementation Agreement to form a combined company Biota Pharmaceuticals, listed on NASDAQ and headquartered in the USA. The Biota mov...http://www.siliconinvestor.com/readmsg.aspx?msgid=280990214/23/2012 6:06:38 AMnigel batesLONDON (ShareCast) - Pharmaceuticals giant AstraZeneca (LSE: AZN.L - news) has announced that it has agreed to acquired California-based biotechnology company Ardea Biosciences (NasdaqGM: RDEA - news) , whose lead product 'Lesinurad' (RDEA594) is currently in Phase III development as a potential treatment for the c...http://www.siliconinvestor.com/readmsg.aspx?msgid=280990044/23/2012 4:43:17 AMnigel batesSurprised no one posted the GSK bid for HGSI: Human Genome Sciences, Inc. – Thu, Apr 19, 2012 5:12 AM EDTHuman Genome Sciences, Inc. (Nasdaq: HGSI - News) today announced that it has received an unsolicited proposal from GlaxoSmithKline plc (GSK) to acquire HGS for $13.00 per share in cash.The HGS Board of Directors...http://www.siliconinvestor.com/readmsg.aspx?msgid=280990034/23/2012 4:42:43 AMtuckOT Humor: Headline on my DowJones news feed today: "Fanatics to acquire Dreams for $3.45 share." Apparently a couple of sports marketing companies, with Dr. Philip Frost involved in one. Cheers, Tuckhttp://www.siliconinvestor.com/readmsg.aspx?msgid=280843114/16/2012 10:02:35 AMtuckSpectrum buying Allos for $1.82 plus CVRs for EU milestones for Folotyn. Sees marketing synergy. Cheers, Tuckhttp://www.siliconinvestor.com/readmsg.aspx?msgid=280624754/5/2012 10:04:18 AMdr.praveenAmylin jumps 46% to $22.50 after Bloomberg reports rejection of takeover bid finance.yahoo.com  PS: I have a small position http://www.siliconinvestor.com/readmsg.aspx?msgid=280418443/28/2012 9:31:00 AMIan@SI ISTA Pharm to be acquired by Bausch + Lomb for $9.10/share in cash ( ISTA) 8.38 +0.08 : Co announced that they have signed a definitive agreement under which Bausch + Lomb ("the Company") will acquire ISTA for $9.10 per share in cash, or a total of approximately $500 million. The transaction, which has been unani...http://www.siliconinvestor.com/readmsg.aspx?msgid=280384933/26/2012 8:39:44 PMnigel batesWESTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Idec (NASDAQ: BIIB - News) and Stromedix, Inc. today announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc., a privately held biotechnology company focused on innovative therapies for fibrosis and organ fai...http://www.siliconinvestor.com/readmsg.aspx?msgid=279475102/14/2012 9:15:27 AMpgo-neilAMGN buys MITI for $11 per share... This is really too bad, would have enjoyed seeing MITI mature and prosper. finance.yahoo.com  THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN - News) and Micromet, Inc. (NASDAQ: MITI - News) today announced that the companies have ent...http://www.siliconinvestor.com/readmsg.aspx?msgid=279070591/26/2012 8:14:10 AMnigel batesTHOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN - News) and Micromet, Inc. (NASDAQ: MITI - News) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its ...http://www.siliconinvestor.com/readmsg.aspx?msgid=279070551/26/2012 8:13:31 AMmopgcwhttp://www.siliconinvestor.com/readmsg.aspx?msgid=279045031/25/2012 10:48:05 AMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=279039581/25/2012 1:48:55 AMtuckRoche Diagnostics takes out Illumina for $44.50. Dunno if you still own this. Cheers, Tuckhttp://www.siliconinvestor.com/readmsg.aspx?msgid=279039541/25/2012 1:44:48 AMDewDiligence_on_SIIDIX takeout vig is somewhat silly insofar as NVS has the practical ability to block almost any deal.http://www.siliconinvestor.com/readmsg.aspx?msgid=278728621/10/2012 5:08:23 PMscaram(o)uchefrom a long-term vrtx holder (sold after approval).............. pfffffffffffffffffffffffffffbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbttt! :-(http://www.siliconinvestor.com/readmsg.aspx?msgid=278726981/10/2012 4:03:42 PMtuckBMS' takeout of Inhibitex (INHX) for $2.5 billion ($26/share) represents an astonishing 163% premium. Since then -- the 7th -- and still today, other HCV plays have been running on takeout vig. IDIX, for example. Cheers, Tuckhttp://www.siliconinvestor.com/readmsg.aspx?msgid=278726101/10/2012 3:27:41 PMscaram(o)uchemasshightech.com  Wednesday, December 21, 2011 Millennium adding two cancer programs via Intellikine buy By Lori Valigra, Mass High Tech correspondent Millennium: The Takeda Oncology Company will add two cancer drug candidates as part of Japanese parent Takeda Pharmaceutical Company Ltd.’s acquisition of Intelli...http://www.siliconinvestor.com/readmsg.aspx?msgid=2784079012/22/2011 6:06:04 PMscaram(o)ucheold stuff..... Plexxikon..... couldn't find this info in the thread when I went looking for it, so..... Daiichi Sankyo To Acquire Plexxikon Deal Accelerates Expansion of Oncology Franchise Berkeley, CA—February 28, 2011 Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Co...http://www.siliconinvestor.com/readmsg.aspx?msgid=2781544312/9/2011 3:13:23 PMDewDiligence_on_SIThe 89% premium is the highest ever in a biotech deal valued at more than $10B, as far as I know: investorshub.advfn.com http://www.siliconinvestor.com/readmsg.aspx?msgid=2777933711/21/2011 2:07:58 PMChris08Gilead (GILD) buys VRUS for $137 a share. Apparently GILD decided to catch up fast in HCV therapies.http://www.siliconinvestor.com/readmsg.aspx?msgid=2777862011/21/2011 9:49:25 AMtuckhttp://www.siliconinvestor.com/readmsg.aspx?msgid=2775191211/7/2011 2:07:47 PMtuckCubist takes out Adolor for 190m plus CVRs (actually, called CPRs here, gotta like that!) >>LEXINGTON, Mass. & EXTON, Pa.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST - News) and Adolor Corporation (NASDAQ: ADLR - News) today announced that they have signed a definitive ...http://www.siliconinvestor.com/readmsg.aspx?msgid=2772219810/24/2011 11:05:27 AMnigel batesSAN DIEGO, Oct. 17, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that it has entered into a definitive merger agreement to be acquired by Roche. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys...http://www.siliconinvestor.com/readmsg.aspx?msgid=2770605510/17/2011 4:45:11 AMSteve LoknessCALP which has been on a slow steady climb, gets a 40%plus premium and still - look at the attorney's massing to represent the poor shareholders.http://www.siliconinvestor.com/readmsg.aspx?msgid=276266549/9/2011 2:02:18 PM